by Raynovich Rod | Oct 20, 2016 | Biopharmaceuticals, Clinical Diagnostics and Tools
Microbiomes: A New Paradigm for Drug Discovery? Focus: Drugs From Gut Bacteria You may have read a few articles about the impact of the microbiomes and their impact on diets, digestion and nutrition but now there is the potential of discovering new therapies from...
by Raynovich Rod | Oct 11, 2016 | Clinical Diagnostics and Tools
Update-1 Biotechs Sinking Again …IBB down 2.48%, ILMN down another 2% Related sequencing stocks: FMI down 1.75%, PACB flat at $8.40 Illumina (ILMN) Shares Crash on Revenue Miss Illumina (ILMN) shares crashed 25% to $139, after a warning on third quarter sales ....
by Raynovich Rod | Sep 6, 2016 | Clinical Diagnostics and Tools
M&A Deal of the Day: Cepheid (CPHD) up 50% Over Friday Close on Cash Buyout We have been spending too much time on biopharma. It is time to dust off our Dx and Tools portfolio, which is on hold, and find some value stocks for Q4 moves. We did an update in Q4 of...
by Raynovich Rod | Aug 18, 2016 | 2024 Rayno Tools and Diagnostics Portfolio, Clinical Diagnostics and Tools
Illumina (ILMN) Up 3 % to $174 on Buyout Speculation in Gene Sequencing Illumina, Inc. (ILMN) was up as much as 12 points earlier today on a rumored buyout from Thermo Fisher Scientific Inc. (TMO). Thermo bought another major player in sequencing Life Techologies for...
by Raynovich Rod | Aug 10, 2016 | Biopharmaceuticals, Clinical Diagnostics and Tools
Update August 15 : Biotech Leads But Healthcare Sector Lags IBB up 0.92% to $295, XBI up 1.33% to $63.35, XLV up 0.17% to $74.91 The tape was pretty decent despite a quiet day with ALXN up 1.97%, AMGN up 1.49% and CELG up 1.08%. Mid-caps also found bids: ALKS up...
by Raynovich Rod | Jul 5, 2016 | 2024 Rayno Tools and Diagnostics Portfolio, 2025 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Foundation Medicine (FMI) New Pick at $20.40 We have added Foundation Medicine (FMI) to our core portfolio because of their leadership position in pharmacogenomics and molecular medicine for cancer care. The Foundation One genomic profile helps physicians make...
by Raynovich Rod | Jun 14, 2016 | Biopharmaceuticals, Clinical Diagnostics and Tools, Macro
BIO International 2016 : “Imagine Who You will Meet” was an Appropriate Theme Healthcare Disruption Is Creating Reform BIO 2016 was an excellent meeting as usual because of the opportunity to hear thought leaders, policy makers, scientists and make...
by Raynovich Rod | Jun 3, 2016 | Biopharmaceuticals, Clinical Diagnostics and Tools
BIO International Conference-Trends in the Biotechnology Industry We will be attending BIO International Convention in San Francisco next week and will provide news updates on relevant topics such as Personalized Medicine, biopharma drug policy and pricing, and next...
by Raynovich Rod | Jun 2, 2016 | Clinical Diagnostics and Tools
Update -1 NH closes at $18.59 up 32.79% on volume of 3.3M shares. High was $21 low was $16.11. Market cap is $2.1B. Focus of the Company is personalized healthcare utilizing a unique software platform (NantOS) applying molecular diagnostics and genomics on patient...
by Raynovich Rod | Apr 27, 2016 | Biopharmaceuticals, Clinical Diagnostics and Tools, Macro
Biotech Bear Market: XLV —A Large Cap Healthcare ETF Outperforms We have compared the performance of top mutual funds in the past and thought it would be interesting to see what happens in a bear market which began in September of 2015. Our last review was in...
